Proteomics · Diagnostics · DTC
Market Opportunity
$13B Combined current
$30B Combined projected
$100B+ Convergence TAM
← Index
Market Sizing  ·  2025–2035

Today, there are two preventive health markets.
Tomorrow, their convergence will create a third.

Synoptic Bio enters via simultaneous clinical and DTC channels: a Laboratory Developed Test for cancer or neurodegeneration and an analytics API powering 23andMe's proteomics platform, before scaling into the emerging $100B+ population-scale preventive health market.

$5B → $10B Single-disease clinical diagnostics Lung cancer · Dementia Screening · Trial enablement Grand View Research, 2025 $4B → $9B Direct-to-consumer molecular health Analytics API · 23andMe Longitudinal monitoring Mordor Intelligence, 2025 $100B+ Population-scale preventive health Multi-disease diagnostics AI-assisted intervention Grand View Research, 2025
Market Breakdown
Market 1  ·  Clinical
Single-disease clinical diagnostics
$5B → $10B
~10–12% CAGR  ·  2025–2032  ·  Lung cancer diagnostics segment

Protein-biomarker-based tests for early-stage cancer or neurodegeneration: high-risk patient stratification, population screening, and clinical trial enrichment. Near-term revenue with a clear LDT regulatory pathway.

Lung cancer LDT Dementia LDT High-risk stratification Trial enablement
Synoptic's entry
R#0–R#2 deliver platform validation, a multi-protein biomarker signature, and multi-cohort clinical evidence. First commercial product: an LDT for lung cancer or dementia early detection, launched via CLIA-certified lab partnership.
Market data: lung cancer diagnostics
1
Grand View Research, 2025 Global lung cancer diagnostics market: $5.35B (2025) → $9.45B (2034) at ~6.5% CAGR. Growth driven by rising incidence, expanded USPSTF low-dose CT screening eligibility (age 50–80, ≥20 pack-years), and increasing integration of molecular and liquid biopsy diagnostics into standard clinical workup. GVR lung cancer report ↗
2
Siegel RL et al. CA: A Cancer Journal for Clinicians, 2025 ~226,650 new US lung cancer cases expected in 2025; lung cancer generates the largest share of oncology diagnostics volume, driven by staging workup, molecular profiling prior to treatment selection, and recurrence monitoring, each requiring repeated, billable diagnostic tests throughout the patient journey. Cancer Statistics 2025 ↗
Market data: Alzheimer's / dementia diagnostics
3
Alzheimer's Association. Alzheimers & Dementia, 2024 (peer-reviewed) Total US Alzheimer's and dementia healthcare costs: $360B in 2024, projected to exceed $1 trillion by mid-century. 6.7M Americans currently living with Alzheimer's, growing to 13.8M by 2050. This economic burden, combined with current confirmatory diagnostic costs (amyloid PET >$4,000; lumbar puncture), creates sustained payer pressure for affordable blood-based alternatives and a structurally large, growing diagnostics market. AA Facts & Figures 2024 ↗
4
Precedence Research / Grand View Research, 2024 Alzheimer's diagnostics market: $8.95B (2024) → $25.53B (2034) at ~11% CAGR. Blood-based biomarker sub-segment: $140M (2024) → $429M (2033) at 15% CAGR, the fastest-growing segment in specialty diagnostics, accelerated by FDA clearance of the first plasma p-tau217 assay (2025) and payer adoption pathways now forming across major US health systems. Precedence Research ↗
Market 2  ·  DTC
Direct-to-consumer molecular health
$4B → $9B
~9% CAGR  ·  2024–2033  ·  Molecular lab testing, exc. wearables

Consumer-direct access to molecular health data: at-home testing, subscription panels, organ-specific aging scores, and longitudinal biomarker tracking, all without a clinical referral.

Analytics API 23andMe proteomics Longitudinal monitoring Subscription model
Synoptic's entry
Simultaneous launch alongside the LDT: a proteomics analytics API for 23andMe's DTC platform, converting their user base's raw protein data into clinically-meaningful signatures. Recurring API revenue without Synoptic owning the consumer relationship.
Market data: DTC molecular lab testing
1
Mordor Intelligence, 2025 DTC laboratory testing market (molecular; excludes wearables and remote monitoring devices): $4.3B (2024) → $9.3B (2033) at 8.9% CAGR. Growth driven by rising consumer demand for at-home blood and saliva molecular panels, expanding test menus across biochemical, hormonal, genomic, and proteomic categories, and increasing willingness to pay for actionable health data without a clinical referral. Mordor Intelligence ↗
2
The Lancet, 2024 Global DTC testing market predicted to exceed $9B by 2033; new biochemical and genetic consumer tests entering the market at approximately 10 new offerings per day, confirming structural, sustained consumer demand for molecular health data outside the clinical referral pathway, with particular growth in blood-based panels. The Lancet 2024 ↗
3
JAMA Internal Medicine, 2023 Systematic analysis of US DTC laboratory testing companies: documents rapid sector expansion across biochemical, hormonal, genomic, and proteomic panels; broadening test menus and evolving regulatory frameworks confirm DTC lab testing as a commercially viable and structurally growing category, distinct from wearables and consumer device markets. JAMA Intern Med 2023 ↗
Market 3  ·  Convergence
Population-scale preventive health
$100B+
Precision medicine + diagnostics + therapeutics convergence  ·  2030+

The emerging category unlocked when multi-disease molecular diagnostics, preventive AI-assisted intervention tools, and therapeutics converge at population scale. Created by the intersection of markets 1 and 2: a new third market that does not yet fully exist.

Multi-disease diagnostics AI-assisted intervention Population screening Preventive therapeutics
Synoptic's long-term position
The biomarker platform (R#0–R#2), microsampling bridge (R#3), and DTC analytics API together build the IP portfolio, biobank relationships, and analytical infrastructure that anchors a population-scale preventive health product at Series B and beyond.
Market data: precision medicine convergence
1
Grand View Research, 2025 Global precision medicine market (molecular diagnostics + targeted therapeutics + companion diagnostics): ~$96B (2023), projected at 12.4% CAGR through 2030, implying a market exceeding $200B before 2032. Fastest-growing sub-segments include multi-cancer early detection, liquid biopsy, and AI-assisted molecular diagnostics: the specific convergence Synoptic's multi-disease proteomics platform is designed to serve. GVR precision medicine ↗
2
Alzheimer's Association (Alzheimers & Dementia, 2024) · ACS Cancer Statistics, 2025 · ADA Economic Costs, 2022 Aggregate annual US economic burden across three core disease areas: Alzheimer's and dementia ($360B), cancer care (NCI: $246B projected by 2030), diabetes ($413B). Shifting detection of these conditions 12–18 months earlier through population-scale proteomics generates disproportionate economic value to payers, self-insured employers, and health systems, establishing the $100B+ addressable market for the analytical infrastructure enabling it. AA Facts & Figures 2024 ↗
3
NHS-Galleri Trial, 2023 · CMS MCED Coverage Review, 2024 Health systems are deploying multi-cancer early detection at population scale now: the NHS-Galleri trial enrolled 140,000 participants across 25 sites; CMS initiated formal coverage review for MCED tests; Grail (Galleri), Guardant (Shield), and Exact Sciences have each launched commercial multi-cancer screening products. Proteomics-based multi-disease detection is the next generation of this emerging category.
★
Sizing note The $100B+ figure represents the convergence of clinical diagnostics, consumer molecular health, and preventive therapeutics into a unified population health platform. This market does not yet exist as a discrete category; it is created by the intersection of Markets 1 and 2. Addressable value accrues primarily to the analytical and biomarker infrastructure layer: where Synoptic operates.
Synoptic's Market Entry Sequence
Phase 1  ·  Seed stage  ·  2025–2027
R#0 + R#1 + R#2
Clinical LDT launch

Platform validation on Nomic Omni 1000 → multi-protein biomarker discovery in 125,000-sample biobank → multi-cohort validation. First commercial product: an LDT for lung cancer or dementia, distributed via CLIA lab partner. Simultaneous 23andMe analytics API launch.

Clinical diagnostics market  ·  $5B → $10B
Phase 2  ·  Series A  ·  2026–2028
R#3
DTC microsampling bridge

Analytical validation of plasma-to-dried-blood-spot equivalence enables at-home finger-prick proteomics, with no venepuncture required. Unlocks a direct consumer channel alongside the existing 23andMe API revenue, and dramatically lowers the cost of population-scale sample collection.

DTC molecular health  ·  $4B → $9B
Phase 3  ·  Growth stage  ·  2028+
Multi-disease platform
Population-scale

The proteomics platform generalises beyond single-disease indication to multi-disease molecular diagnostics. Combining clinical LDT validation, at-home sampling infrastructure, and AI-assisted intervention tools positions Synoptic to help define the $100B+ convergence market.

Population-scale preventive health  ·  $100B+
Full Evidence & Citation Index